Fierce Pharma2h
In patent clash over injectable Keytruda, Merck and Halozyme dig in for a fight
Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma ...
Medical Dialogues6h
Merck injected version of Keytruda faces possible patent challenge: Report
Merck's newly developed injected version of its blockbuster cancer drug, Keytruda, may be at the center of a potential patent ...
New Version of Merck’s Blockbuster Cancer Drug Threatened by Patent Battle
The company has asked the U.S. patent office to reconsider patents that could prevent it from selling an update to Keytruda.
Investing Snacks10h
Merck’s Keytruda Injection Faces Patent Battle With Halozyme
Merck’s push to make Keytruda injectable has triggered a patent dispute with Halozyme. The conflict arises over the use of ...
Devdiscourse5h
Reuters Health News Summary
"We are currently engaging with market participants," a spokesperson for South Africa's Competition Commission told Reuters, declining to provide details. USAID cuts put tuberculosis response in peril ...
Piper Sandler Keeps Their Hold Rating on Halozyme (HALO)
Piper Sandler analyst Joseph Catanzaro maintained a Hold rating on Halozyme (HALO – Research Report) today and set a price target of $53.00.
Investing Snacks10h
AbbVie Expands SKYRIZI Access in Canada for Colitis
AbbVie has expanded the availability of SKYRIZI in Canada for ulcerative colitis, strengthening its presence in the ...